“Whoa! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Assessment of Advantages and Disadvantages of Agents Used For Therapeutic Anticoagulation

Warfarin is an awful drug. That is not to say that it is not also a lifesaving drug—it is. So many randomized controlled trials have demonstrated warfarin's remarkable ability to reduce embolic stroke in patients with atrial fibrillation, the indication for warfarin that this article focuses on, that it would be unethical to perform another placebo-controlled warfarin trial in patients with atrial fibrillation who are able to tolerate the drug ( Table 1 ). 1-6 However, its numerous and profound limitations include a narrow therapeutic range, requiring patients to have at least monthly monitoring, a highly variable bioavailability between individuals, an enormous number of both drug–drug and diet–drug interactions, and the existence of common genetic polymorphisms that influence drug effect, leading many to wonder whether the Food and Drug Administration (FDA) would approve warfarin if it came to review in the current climate. Currently there are more than a dozen anticoagulant drugs under development in an attempt to replace warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation; two of them, dabigatran and rivaroxaban, have been approved. Some of these anticoagulants, like dabigatran, are thrombin (Factor II) inhibitors; others, like rivaroxaban, apixaban, and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Disease-a-Month Elsevier
Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.